Acquired apparent mineralocorticoid excess induced by compound glycyrrhizin tablets: A case report and literature review.

Int J Clin Pharmacol TherSep 9, 2026
Case ReportEndocrinology

Yu Li, Juan Du, Guojie Ma

✦ AI-curated · Sources linked

Case in brief

A 57-year-old male developed severe hypertension and hypokalemia after 30 days of treatment with compound glycyrrhizin tablets. Laboratory tests showed profound hypokalemia and metabolic alkalosis, with suppressed plasma renin activity and aldosterone levels, leading to a diagnosis of acquired apparent mineralocorticoid excess (AME). Treatment with amlodipine and potassium supplementation resolved his symptoms, and follow-up confirmed stable blood pressure and normalized potassium levels.

Diagnostic / clinical pearl

Clinicians should consider acquired apparent mineralocorticoid excess in patients presenting with hypertension and hypokalemia, particularly those using glycyrrhizin-containing products.

Source

PubMed · PMID 42544526

Published in Int J Clin Pharmacol Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

JAMASep 8, 2026Open accessRead summary
Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchPsychiatry

The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.

This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders…

Lancet PsychiatrySep 10, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.